{"id":62561,"date":"2026-04-07T21:45:14","date_gmt":"2026-04-07T13:45:14","guid":{"rendered":"https:\/\/flcube.com\/?p=62561"},"modified":"2026-04-07T21:45:15","modified_gmt":"2026-04-07T13:45:15","slug":"gan-lee-pharmaceuticals-launches-chinas-first-ar-targeting-protac-into-phase-i-trial-for-advanced-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62561","title":{"rendered":"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer"},"content":{"rendered":"\n<p><strong>Gan &amp; Lee Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603087:SHA\">SHA: 603087<\/a>) has received <strong>IND approval from China\u2019s National Medical Products Administration (NMPA)<\/strong> to initiate a <strong>Phase I clinical trial<\/strong> of <strong>GLR2037<\/strong>, its <strong>Category 1 chemical drug<\/strong> and first-in-class <strong>androgen receptor\u2013proteolysis-targeting chimera (AR PROTAC)<\/strong>, in patients with <strong>advanced prostate cancer<\/strong>.<\/p>\n\n\n\n<p>GLR2037 represents a strategic entry into the next generation of oncology therapeutics, leveraging <strong>PROTAC technology<\/strong>\u2014an emerging modality that hijacks the cell\u2019s <strong>ubiquitin-proteasome system (UPS)<\/strong> to selectively degrade disease-causing proteins previously deemed \u201cundruggable\u201d by conventional small-molecule inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-regulatory-status\">Development &amp; Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>GLR2037<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>NMPA Category 1 (novel chemical entity)<\/td><\/tr><tr><td><strong>Modality<\/strong><\/td><td>Androgen Receptor (AR)\u2013targeting PROTAC<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced prostate cancer (castration-resistant and metastatic forms)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase I (first-in-human, dose escalation)<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA IND clearance granted Q2 2026<\/td><\/tr><tr><td><strong>Global Context<\/strong><\/td><td>Among the first AR PROTACs to enter clinical development outside the U.S.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-rationale\">Scientific Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Unlike traditional anti-androgens that merely block AR signaling, <strong>GLR2037 induces complete degradation of the androgen receptor<\/strong>, eliminating both genomic and non-genomic AR functions.<\/li>\n\n\n\n<li><strong>Target Scope<\/strong>: Addresses key resistance mechanisms in late-stage prostate cancer, including <strong>AR splice variants (e.g., AR-V7)<\/strong> and <strong>overexpressed full-length AR<\/strong>\u2014targets inaccessible to current therapies like enzalutamide or abiraterone.<\/li>\n\n\n\n<li><strong>Platform Potential<\/strong>: Success would validate Gan &amp; Lee\u2019s internal <strong>PROTAC discovery engine<\/strong>, opening pathways to target other oncogenic transcription factors.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-amp-strategic-implications\">Competitive &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Need<\/strong>: Over <strong>150,000 new prostate cancer cases annually in China<\/strong>, with limited options after second-line hormonal therapy failure.<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: GLR2037 joins a global race led by Arvinas (ARV-110) and Kyowa Kirin, but is the <strong>first domestically developed AR PROTAC<\/strong> in China, positioning Gan &amp; Lee as a pioneer in targeted protein degradation in Asia.<\/li>\n\n\n\n<li><strong>IP Position<\/strong>: Backed by composition-of-matter and method-of-use patents filed in China, U.S., and EU.<\/li>\n\n\n\n<li><strong>Pipeline Impact<\/strong>: Positive data could accelerate partnerships with multinational pharma seeking China-accessible degraders.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking information regarding clinical development and regulatory progress. Actual results may differ due to trial outcomes, safety findings, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603087_20260404_6QWZ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603087_20260404_6QWZ.\"><\/object><a id=\"wp-block-file--media-74da6763-a517-404b-b6ab-97a42d41cef6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603087_20260404_6QWZ.pdf\">603087_20260404_6QWZ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603087_20260404_6QWZ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-74da6763-a517-404b-b6ab-97a42d41cef6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Gan &amp; Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China\u2019s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[421,1120],"class_list":["post-62561","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-gan-lee-pharmaceuticals","tag-sha-603087"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gan &amp; Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China\u2019s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of GLR2037, its Category 1 chemical drug and first-in-class androgen receptor\u2013proteolysis-targeting chimera (AR PROTAC), in patients with advanced prostate cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62561\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"Gan &amp; Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China\u2019s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of GLR2037, its Category 1 chemical drug and first-in-class androgen receptor\u2013proteolysis-targeting chimera (AR PROTAC), in patients with advanced prostate cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62561\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T13:45:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T13:45:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62561#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62561\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer\",\"datePublished\":\"2026-04-07T13:45:14+00:00\",\"dateModified\":\"2026-04-07T13:45:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62561\"},\"wordCount\":355,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gan &amp; Lee Pharmaceuticals\",\"SHA: 603087\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62561#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62561\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62561\",\"name\":\"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-07T13:45:14+00:00\",\"dateModified\":\"2026-04-07T13:45:15+00:00\",\"description\":\"Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China\u2019s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of GLR2037, its Category 1 chemical drug and first-in-class androgen receptor\u2013proteolysis-targeting chimera (AR PROTAC), in patients with advanced prostate cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62561#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62561\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62561#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China\u2019s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of GLR2037, its Category 1 chemical drug and first-in-class androgen receptor\u2013proteolysis-targeting chimera (AR PROTAC), in patients with advanced prostate cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62561","og_locale":"en_US","og_type":"article","og_title":"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer","og_description":"Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China\u2019s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of GLR2037, its Category 1 chemical drug and first-in-class androgen receptor\u2013proteolysis-targeting chimera (AR PROTAC), in patients with advanced prostate cancer.","og_url":"https:\/\/flcube.com\/?p=62561","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-07T13:45:14+00:00","article_modified_time":"2026-04-07T13:45:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62561#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62561"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer","datePublished":"2026-04-07T13:45:14+00:00","dateModified":"2026-04-07T13:45:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62561"},"wordCount":355,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gan &amp; Lee Pharmaceuticals","SHA: 603087"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62561#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62561","url":"https:\/\/flcube.com\/?p=62561","name":"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-07T13:45:14+00:00","dateModified":"2026-04-07T13:45:15+00:00","description":"Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China\u2019s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of GLR2037, its Category 1 chemical drug and first-in-class androgen receptor\u2013proteolysis-targeting chimera (AR PROTAC), in patients with advanced prostate cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62561#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62561"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62561#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gan &amp; Lee Pharmaceuticals Launches China\u2019s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62561"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62561\/revisions"}],"predecessor-version":[{"id":62565,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62561\/revisions\/62565"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}